Vera Therapeutics stock drops 3% today as biotech slips into year-end trading
Vera Therapeutics shares dropped 3.4% to $50.45 in afternoon trading Tuesday, underperforming as biotech ETFs also declined. The company’s lead drug atacicept is under FDA review for IgA nephropathy, with investors watching for regulatory updates. No new company announcements explained the drop. Rival Travere Therapeutics also fell 3.4%.